Michigan lawmakers are set to vote on a package of bills that would make sweeping changes to the state’s 2008 voter-approved medical cannabis law, including reducing the number of patients allowed per caregiver and limiting the number of plants caregivers can grow at one time from 60 to 12, Michigan Advance reports.
MINDCURE announces an LOI with Awaken Life Sciences for the deployment of MINDCURE's iSTRYM digital therapeutics platform in Awaken's addiction treatment clinics.
MINDCURE announces its Q1 fiscal 2022 results, including initial release of its iSTRYM platform. Cash and equivalents of CAD$15.6 million as of August 31, 2021.
The rapidly expanding networks of psychedelics-based treatment clinics is a horse race where EVERYONE is a winner.
MindMed announces a new R&D initiative focused on an MDMA derivative, and aimed at treating social anxiety.
Cybin receives IND authorization from the FDA to study ketamine's psychedelic effect on the cerebral cortex.
Washington, D.C. voters are strongly in favor of proposals to broadly decriminalize drugs and establish harm reduction centers, a new poll found.
Levitee Labs announces new credit facility for up to CAD$12 million to finance expansion of its clinics network.
Psychedelic drugs are all over the news. Not just general news but also business media. Big news. Big Business.
After a series of delays and legal obstacles, the state of Rhode Island finally appears ready to dole out new licenses for medical marijuana dispensaries.
The Internal Revenue Service would like to get paid—and it’d help if the marijuana industry had access to banks like companies in other legal markets, an official with the federal department said.
The European country of Luxembourg, which shares borders with Belgium, Germany…
A fourth Massachusetts city has enacted a psychedelics policy change, with members of the Easthampton City Council voting on Wednesday in favor of a resolution urging the decriminalization of certain entheogenic substances and other drugs.
Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
The UK drug regulator (MHRS) has granted Small Pharma Fast-Track Designation with respect to SPL026 for Major Depressive Disorder (MDD).
